# CRISPR in Primary Cells to Study HIV-Host Function

> **NIH NIH P50** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $341,679

## Abstract

The HARC Center has made rapid progress in systematically characterizing physical interactions between HIV
proteins and host cell pathways using proteomic approaches. The functional roles of these emerging pathways
now need to be experimentally tested, which requires targeted genome engineering in primary human T cells.
CRISPR-Cas9 is a revolutionary technology that enables re-writing human genetic information in a
programmable, site-specific manner. Moreover, the HARC Center recently overcame longstanding hurdles in
performing genome editing in primary human T cells. We achieved highly efficient knock-out and knock-in
genome engineering in human CD4+ T cells using Cas9:guide RNA ribonucleoproteins (Cas9 RNPs). The
ability to precisely replace DNA sequences in the genome of functional T cells now provides unprecedented
opportunities to test the mechanistic effects of specific host and viral genetic factors in HIV pathogenesis.
Our new tools for genetic manipulation of human T cells strongly complement the HARC Center’s strengths in
structural biology and proteomics. We now propose to expand our ongoing dissection of the mechanistic
effects of host factors in primary human T cells. These systematic efforts will identify pathways regulated by
HIV-interacting factors and functionally test their roles in HIV infection. These studies offer novel means to
integrate human genetics and genome engineering with the existing strengths of the HARC Center. Cas9
RNPs will not only allow gene ablation, but will also allow us to edit specific domains or even replace individual
amino acids. We have a particular interest in the functional and structural consequences of naturally occurring
genetic variants associated with resistance to HIV or delayed progression to AIDS. Finally, Cas9 RNP genome
engineering will allow affinity tagging of endogenous host factors in primary cells to enable unprecedented
studies of macromolecular complexes involving human and HIV proteins. Collectively, these genetic studies
will strengthen the central HARC mission to understand interactions between HIV viral proteins and host
molecules and should open new experimental and therapeutic avenues for the broader HIV research
community.

## Key facts

- **NIH application ID:** 9993235
- **Project number:** 5P50AI150476-14
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Alexander Marson
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $341,679
- **Award type:** 5
- **Project period:** 2007-08-27 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9993235

## Citation

> US National Institutes of Health, RePORTER application 9993235, CRISPR in Primary Cells to Study HIV-Host Function (5P50AI150476-14). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/9993235. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*